Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab PET assessment in treatment-refractory sarcoidosis
2006-001816-56Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in sarcoidosis, sponsored by Rigshospitalet. Primary endpoints: FDG-PET disease activity assessment and Chest x-ray assessment of sarcoidosis activity. Started Apr 2006; status: completed.
02
Drugs
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on 2006-001816-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001816-56.